The UK and US have agreed to a major bilateral deal that will ensure no duties on British drug products being sold in the American market.
Key Provisions of the Pact
As part of the deal, the UK has committed to increase expenditure on drugs through the NHS. This commitment secures that import taxes on these key products will stay at zero for a duration of 36 months.
This development comes after earlier threats to dramatically increase duties on branded pharmaceutical imports, with potential rates mentioned reaching 100%.
"This agreement between the United Kingdom strengthens the worldwide climate for cutting-edge drugs and introduces long-overdue balance to American-British medicine commerce," a statement declared.
Trade Significance
Medicines are one of the the United Kingdom's largest export categories to the United States, which is easily the primary buyer for leading UK drugmakers.
Statistics show that in the 12 months to the end of last September, the UK exported medicines valued at £11.1bn to the US. This value accounted for a significant portion of all goods exports in that timeframe.
"This deal secures jobs, boosts investment and facilitates the UK to emerge as a international leader for biotech and pharma," a government official commented.
Specific UK Commitments
The pact involves several notable commitments from the UK:
- Price Threshold Increase: The UK will lift the cost ceiling at which it considers new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to double overall NHS spending on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to control costs will be limited at 15%. Previously, refunds exceeded 20%.
Recent Tensions
The pact takes place against a ongoing dispute between the pharmaceutical industry and the ministers over medicine costs and regulatory access.
This friction were intensified by arguments that US consumers were paying several times more for the identical medicines than people in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been announced toward US facilities.
The Science Minister acknowledged that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had declined as a percentage of its overall budget over the last ten years.
